Source link : https://www.newshealth.biz/health-news/exploratory-analysis-identifies-biomarkers-of-response-in-tnbc/
New biomarker analyses from the phase 3 KEYNOTE-522 trial provide insights into the biological factors that may influence response to pembrolizumab plus chemotherapy in early-stage triple-negative breast cancer (TNBC). The new research, presented by Joyce O’Shaughnessy, MD, at San Antonio Breast Cancer Symposium (SABCS) 2024, also reinforces the broad benefit of this immunotherapy-chemotherapy combination across […]
Author : News Health
Publish date : 2024-12-16 13:36:41
Copyright for syndicated content belongs to the linked Source.